Dizal's ZEGFROVY Hits Primary Endpoint in Pivotal Phase 3 Cancer Trial

Dizal announced on May 29, 2026 that its investigational drug ZEGFROVY met the primary endpoint of superior anti-tumor efficacy in the Phase 3 WU-KONG28 clinical trial. The study compared ZEGFROVY to standard-of-care therapy in patients with a specific solid tumor, though the exact cancer type was not disclosed. Topline data demonstrated a statistically significant improvement in progression-free survival. The company said it plans to submit these results to the U.S. FDA and European Medicines Agency for regulatory approval. Full efficacy and safety data will be presented at a forthcoming medical meeting. ZEGFROVY targets a genetically defined patient population, potentially opening a multibillion-dollar market opportunity. Dizal intends to file marketing applications in major markets by early 2027.